Medindia

X

Reportlinker Adds Crohn's Disease: Future Treatment Scenarios and Opportunities

Thursday, May 12, 2011 General News J E 4
Advertisement

NEW YORK, May 12, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Crohn's disease: future treatment scenarios and opportunities

http://www.reportlinker.com/p0490895/Crohn's-disease-future-treatment-scenarios-and-opportunities.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Changes in therapeutic strategies for Crohn's disease are set to have a profound impact on its treatment landscape, exacerbating current and generating new treatment challenges for doctors, while presenting new and potentially lucrative opportunities for current and future market players. Sociable Pharma conducted in-depth primary research in the US and across Europe with six key opinion leaders to understand how these changes will impact therapy use in the future. We also gauged opinion during the European Crohn's & Colitis Organisation's (ECCO) Annual Congress on the impact that new clinical data for existing and pipeline products will have on treatment strategies employed by inflammatory bowel disease specialists.

HIGHLIGHTS

Identifies the latest treatment trends in Crohn's disease, including the growing importance of "top-down" treatment strategies for moderate-to-severe Crohn's disease

Based on key opinion leader interviews in the US and Europe, as well as the ECCO 2011 conference, supplemented with extensive secondary research on medical evidence and guidelines

Identifies commercial opportunities in Crohn's disease treatment including:

1. Targeting patients naïve to anti-TNF therapies with novel oral inhibitors

2. Combination therapies with helminth in mild-to-moderate disease

3. Improved localized release of corticosteroids to reduce systemic side effects

Assesses future scenarios for Crohn's disease therapies, including:

1. Migration of anti-TNF therapies to new treatment settings

2. Impact of tailored induction and maintenance regimens

3. Future use of antibiotics, probiotics and helminth in mild-to-moderate disease

Executive Summary

Scope of analysis & methodology

Commercial opportunities

Corticosteroids

Aminosalicylates

Immunomodulators

Anti-TNF therapies

Antibiotics

Probiotics

Helminth therapy

New biologics

Novel oral therapies

Future scenarios

Crohn's Disease Treatment Map

Companies mentioned

AstraZeneca

Prometheus

Forest

UCB Pharma

Ferring

Shire

Warner Chilcott

Salix

Alaven

Axcan

Pfizer

Almirall

GSK

Centocor

Merck

TOA Probiotics

Teva

Genzyme

Cellerix

Ovamed

Asphelia

To order this report:

Pathology Industry: Crohn's disease: future treatment scenarios and opportunities

Pathology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626

SOURCE Reportlinker

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Reportlinker Adds Generic Growth Strategies - Manu...
S
Reportlinker Adds Industrial Biotechnology China N...